Drug-resistance mechanisms and tuberculosis drugs

Feuerriegel, Silke; Ellington, Matthew J.; Torok, M. Estee; Javid, Babak; Abubakar, Ibrahim; Peacock, Sharon J.; Burman, William J.; Moore, David Alexander James; Brown, Nicholas M.; Koser, Claudio U.; Liddell, Kathleen; Ismail, Nazir A.; Niemann, Stefan

dc.contributor.author	Koser, Claudio U.
dc.contributor.author	Javid, Babak
dc.contributor.author	Liddell, Kathleen
dc.contributor.author	Ellington, Matthew J.
dc.contributor.author	Feuerriegel, Silke
dc.contributor.author	Niemann, Stefan
dc.contributor.author	Brown, Nicholas M.
dc.contributor.author	Burman, William J.
dc.contributor.author	Abubakar, Ibrahim
dc.contributor.author	Ismail, Nazir A.
dc.contributor.author	Moore, David Alexander James
dc.contributor.author	Peacock, Sharon J.
dc.contributor.author	Torok, M. Estee
dc.date.accessioned	2019-02-06T14:59:06Z
dc.date.available	2019-02-06T14:59:06Z
dc.date.issued	2015
dc.identifier.uri	https://hdl.handle.net/20.500.12866/5535
dc.description.abstract	Bedaquiline and delamanid, novel classes of anti-tuberculosis drugs, have been recently approved for the treatment of multidrug-resistant tuberculosis. Antimicrobial resistance invariably follows the introduction of new drugs, and appropriate drug-susceptibility testing assays are needed to detect resistance and tailor treatment regimens that contain new agents. Given that phenotypic drug-susceptibility testing is slow, technically demanding, and, in some cases, unreliable, future assays are likely to be based on rapid molecular techniques. To design such assays, research to unravel the genetic basis of resistance is urgently required (appendix). The question is how to ensure that this research occurs in a timely way, before the emergence and spread of resistance.	en_US
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	Lancet
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	Humans	en_US
dc.subject	Antitubercular Agents/therapeutic use	en_US
dc.subject	Diarylquinolines/therapeutic use	en_US
dc.subject	Drug Approval	en_US
dc.subject	Mutation/genetics	en_US
dc.subject	Nitroimidazoles/therapeutic use	en_US
dc.subject	Oxazoles/therapeutic use	en_US
dc.subject	Tuberculosis, Multidrug-Resistant/genetics/prevention & control	en_US
dc.title	Drug-resistance mechanisms and tuberculosis drugs	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1016/S0140-6736(14)62450-8
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.00
dc.relation.issn	1474-547X